Alkaptonuria - Many questions answered, further challenges beckon.
| Autor: | Davison, AS, Hughes, AT, Milan, AM, Sireau, N, Gallagher, JA, Ranganath, LR, Davison, A S, Hughes, A T, Milan, A M, Gallagher, J A, Ranganath, L R |
|---|---|
| Předmět: |
ALKAPTONURIA
INBORN errors of metabolism TYROSINE metabolism QUALITY of life PHYSICAL therapy BIOLOGICAL models RESEARCH FERRANS & Powers Quality of Life Index ANIMAL experimentation RESEARCH methodology AMINO acid metabolism disorders EVALUATION research MEDICAL cooperation HYDROCARBONS COMPARATIVE studies RESEARCH funding ENZYME inhibitors CARBOCYCLIC acids MICE |
| Zdroj: | Annals of Clinical Biochemistry; Mar2020, Vol. 57 Issue 2, p106-120, 15p, 1 Color Photograph, 2 Diagrams, 4 Charts |
| Abstrakt: | Alkaptonuria is an iconic rare inherited inborn error of metabolism affecting the tyrosine metabolic pathway, resulting in the accumulation of homogentisic acid in the circulation, and significant excretion in urine. Dating as far back as 1500 BC in the Egyptian mummy Harwa, homogentisic acid was shown to be central to the pathophysiology of alkaptonuria through its deposition in collagenous tissues in a process termed ochronosis. Clinical manifestations occurring as a consequence of this are typically observed from the third decade of life, are lifelong and significantly affect the quality of life. In large supportive and palliative treatment measures are available to patients, including analgesia, physiotherapy and joint replacement. Studying the natural history of alkaptonuria, in a murine model and human subjects, has provided key insights into the biochemical and molecular mechanisms underlying the pathophysiology associated with the disease, and has enabled a better understanding of the common disease osteoarthritis. In the last decade, a major focus has been on an unlicensed disease-modifying therapy called nitisinone. This has been shown to be highly efficacious in reducing homogentisic acid, and it is hoped this will halt ochronosis, thus limiting the clinical complications associated with the disease. A well-documented metabolic consequence of nitisinone therapy is hypertyrosinaemia, the clinical implications of which are uncertain. Recent metabolomic studies have helped understand the wider metabolic consequences of nitisinone therapy. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|